ORIGINAL PAPER
Non-alcoholic fatty liver disease (NAFLD) spectrum in children with type 1 diabetes mellitus evaluated with non-invasive fibrosis score and instrument: A cross-sectional study
1
National Research Centre, Egypt
Submission date: 2021-10-11
Final revision date: 2021-11-23
Acceptance date: 2021-12-06
Publication date: 2022-01-11
Pediatr Pol 2021;96(4):223-230
KEYWORDS
nonalcoholic fatty liver disease (NAFLD)type 1 diabetes mellitusfibrosis (FIB)-4 indexpaediatric NAFLD fibrosis index (PNFI)
TOPICS
ABSTRACT
Aim of the study:
The aim of the study was to evaluate NAFLD spectrum in children with type 1 of diabetes mellitus (T1DM) by simple fibrosis scores and advanced biochemical markers in association with abdominal ultrasonography (US), Acoustic radiation force impulse elastography (ARFI) and comparing their results.
Material and methods:
A case-control study was conducted on 142children and adolescents with T1DM and79 subjects as controls. Through medical history, clinical examination, and laboratory assessment including glycosylated hemoglobin (HbA1c) levels and liver enzymes including AST and ALT were carried out. Calculation of simple fibrosis scores (AST/ALT ratio, AST to platelet ratio index (APRI), fibrosis (FIB)-4 index, paediatric NAFLD fibrosis index (PNFI) were done. Assessment of advanced biochemical markers including hyaluronic acid (HA) , amino terminal pro peptide of type III collagen (PIIINP) and tissue inhibitor of metalloproteinase 1 (TIMP-1) levels. Also, ELF test were calculated.
Results:
Data of non-invasive fibrosis score, there were statistically significant difference between cases and controls in fibrosis 4 score, Discriminant score also ratio of AST to ALT value (p = 0.009, 0.000 and 0.019) respectively. Also, regarding advanced biochemical markers and ELF score, there were a high statistically significant difference in TMP, Hyaluronic acid and ELF(p = 0.00, 0.044 and 0.00) respectively.
Conclusions:
Our results support that there are available non-invasive biomarkers for hepatic affection in children with T1DM. Obtained results support that there is a going on process in diabetic children could be assessed by AST/ALT ratio, FIB-4 index and ELF Score with performing abdominal sonography while ARFI needed in more advanced stage.
The aim of the study was to evaluate NAFLD spectrum in children with type 1 of diabetes mellitus (T1DM) by simple fibrosis scores and advanced biochemical markers in association with abdominal ultrasonography (US), Acoustic radiation force impulse elastography (ARFI) and comparing their results.
Material and methods:
A case-control study was conducted on 142children and adolescents with T1DM and79 subjects as controls. Through medical history, clinical examination, and laboratory assessment including glycosylated hemoglobin (HbA1c) levels and liver enzymes including AST and ALT were carried out. Calculation of simple fibrosis scores (AST/ALT ratio, AST to platelet ratio index (APRI), fibrosis (FIB)-4 index, paediatric NAFLD fibrosis index (PNFI) were done. Assessment of advanced biochemical markers including hyaluronic acid (HA) , amino terminal pro peptide of type III collagen (PIIINP) and tissue inhibitor of metalloproteinase 1 (TIMP-1) levels. Also, ELF test were calculated.
Results:
Data of non-invasive fibrosis score, there were statistically significant difference between cases and controls in fibrosis 4 score, Discriminant score also ratio of AST to ALT value (p = 0.009, 0.000 and 0.019) respectively. Also, regarding advanced biochemical markers and ELF score, there were a high statistically significant difference in TMP, Hyaluronic acid and ELF(p = 0.00, 0.044 and 0.00) respectively.
Conclusions:
Our results support that there are available non-invasive biomarkers for hepatic affection in children with T1DM. Obtained results support that there is a going on process in diabetic children could be assessed by AST/ALT ratio, FIB-4 index and ELF Score with performing abdominal sonography while ARFI needed in more advanced stage.
REFERENCES (57)
1.
Molleston JP, Schwimmer JB, Yates KP, et al. Histological abnormalities in children with nonalcoholic fatty liver disease and normal or mildly elevated alanine aminotransferase levels. J Pediatr 2014; 164: 707-713.
2.
Alisi A, Manco M, Vania A, et al. Pediatric nonalcoholic fatty liver disease in 2009. J Pediatr 2009; 155: 469-474.
3.
Plesec T, Cruise M. Liver pathology. Pediatric gastrointestinal and liver disease, 5th ed. Elsevier, Philadelphia 2016; 798.
4.
Rashid M, Roberts EA: Nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr 2000; 30: 48-53.
5.
Nobili V, Marcellini M, Devito R, et al. NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice. Hepatology 2006, 44: 458-465.
6.
Farhan R, Alzubaidi MA, Ghayyib SM. Fatty Liver Disease in Children and Adolescents with Type 1 Diabetes Mellitus (Clinical and Diagnostic aspects). J Clin Gastroenterol Hepatol 2018; 2: 14.
7.
Kilpatrick ES, Rigby AS, Atkin SL. Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: “double diabetes” in the Diabetes Control and Complications Trial. Diabetes Care 2007; 30: 707-712.
8.
Regnell SE, Lernmark A. Hepatic steatosis in type 1 diabetes. Rev Diabet Stud 2011; 8: 454-467.
9.
Petit JM, Pedro L, Guiu B, et al. Type 1 diabetes is not associated with an increased prevalence of hepatic steatosis. Diabet Med 2015; 32: 1648-1651.
10.
Leeds JS, Forman EM, Morley S, et al. Abnormal liver function tests in patients with type 1 diabetes mellitus: prevalence, clinical correlations and underlying pathologies. Diabet Med 2009; 26: 1235-1241.
11.
Targher G, Bertolini L, Padovani R, et al. Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes. J Hepatol 2010; 53: 713-718.
12.
West J, Brousil J, Gazis A, et al. Elevated serum alanine transaminase in patients with type 1 or type 2 diabetes mellitus. QJM 2016; 99: 871-876 .
13.
Marten Schulz & Frank TackeIdentifying High-Risk NASH Patients: What We Know so Far .Hepatic Medicine: Evidence and Research 2020; 12: 125-138.
14.
Alkhouri N, McCullough A. Noninvasive Diagnosis of NASH and Liver Fibrosis Within the Spectrum of NAFLD. Gastroenterol Hepatol 2012; 8: 661-668.
15.
Wieckowska A, Mc Cullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: Present and future. Hepatology 2007; 46: 582-589.
16.
Rosenberg WMC, Voelker M, Thiel R, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004; 127: 1704-1713.
17.
Nobili V, Parkes J, Bottazzo G, et al. Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fattyliver disease. Gastroenterology 2009; 136: 160-167.
18.
Alkhouri N, Mansoor S, Giammaria P, et al. The development of the pediatric NAFLD fibrosis score (PNFS) to predict the presence of advanced fibrosis in children with nonalcoholic fatty liver disease. PloS One 2014; 9: e104558.
19.
Alkhouri N, Carter-Kent C, Lopez R, et al. A combination of the pediatric NAFLD fibrosis index and enhanced liver fibrosis test identifies children with fibrosis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2011; 9: 150-155.
20.
Nobili V, Alisi A, Vania A, et al. The pediatric NAFLD fibrosis index: a predictor of liver fibrosis in children with non-alcoholic fatty liver disease. BMC Med 2009; 7: 21.
21.
Lee MJ, Kim MJ, Han KH, Yoon CS. Age-related changes in liver, kidney, and spleen stiffness in healthy children measured with acoustic radiation force impulse imaging. Eur J Radiol 2013; 82: e290-e294.
22.
Singh D, Das CJ, Baruah MP. Review Article Imaging of non alcoholic fatty liver disease: A road less travelled. Indian J Endocrinol Metab 2013; 17: 990-995.
23.
Hiernaux J, Tanner JM. Growth and physique. In: Weiner JS, Lourie JA (eds.). Human biology, a guide to field methods. Davis Company, Philadelphia 1969; 2-42.
24.
Snyder N, Gajula L, Xiao SY, et al. APRI: an easy and validated predictor of hepatic fibrosis in chronic hepatitis C. J Clin Gastroenterol 2006; 40: 535-542.
25.
Martínez SM, Crespo G, Navasa M, Forns X. Noninvasive assessment of liver fibrosis. Hepatology 2011; 53: 325-335.
26.
Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis patients with HIV/HCV co-infection. Hepatology 2006; 43:1317-1325.
27.
Mansoor S, Collyer E, Alkhouri N. A Comprehensive Review of Noninvasive Liver Fibrosis Tests in Pediatric Nonalcoholic Fatty Liver Disease Curr Gastroenterol Rep 2015; 17: 23.
28.
Jayanta P. Recent advances in non-invasive diagnosis and medical management of non-alcoholic fatty liver disease in adult .Egyptian Liver Journal 2020; 10: Article number: 37.
29.
Valls C, Iannacconne R, Alba E, et al. Fat in the liver: Diagnosis and characterization. Eur Radiol 2006; 16: 2292-308.
30.
Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 745-750.
31.
Palmeri ML, Wang MH, Dahl JJ, et al. Quantifying hepatic shear modulus in vivo using acoustic radiation force. Ultrasound Med Biol 2008; 34: 546-558.
33.
Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37: 1202-1219.
34.
Rafiq N, Bai C, Fang Y, et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009; 7, 234-238.
35.
Schwimmer JB, Dunn W, Norman GJ, et al. SAFETY study: alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease. Gastroenterology 2010; 138: 1357-1364.
36.
Vos MB, Abrams SH, Barlow SE, et al. NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children: recommendations from the expert committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr 2017; 64: 319-334.
37.
Ismail N, Abd ElBaky A, Ibrahim M, et al. Role of Serum CytoKeratin-18 and Platelets Count as Noninvasive Markers in Diagnosis of Nonalcoholic Fatty Liver Disease in Children with T1DM. Pediatria Polska 2020; 95: 141-148.
38.
Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003; 37: 1286-1292.
39.
Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137: 1-10.
40.
Flisiak-Jackiewicz M, Lebensztejn DM. Update on pathogenesis, diagnostics and therapy of nonalcoholic fatty liver disease in children. Clin Exp Hepatol 2019; 5: 11-21.
41.
41 El-Karaksy HM, Anwar G, Esmat G, et al. Prevalence of hepatic abnormalities in a cohort of Egyptian children with type 1 diabetes mellitus. Pediatric Diabetes 2010: 11: 462-470.
42.
Al-Hussaini AA, Sulaiman NM, Alzahrani MD, et al. Prevalence of hepatopathy in type 1 diabetic children. BMC Pediatr 2012; 12: 160.
43.
Hanquinet S, Courvoisier D, Kanavaki A, et al. Acoustic radiation force impulse imaging-normal values of liver stiffness in healthy children. Pediatr Radiol 2013; 43: 539-544.
44.
44 Kummer S, Klee D, Kircheis G, et al Screening for non-alcoholic fatty liver disease in children and adolescents with type 1 diabetes mellitus: a cross-sectional analysis. Eur J Pediatr 2017; 176: 529-536.
45.
Loaeza Del Castillo A, Paz PF, Oviedo CE, et al. AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis. Ann Hepatol 2008; 7: 350-357.
46.
Mc Googan KE, Smith PB, Choi SS, et al. Performance of the AST-to-platelet ratio index as a noninvasive marker of fibrosis in pediatric patients with chronic viral hepatitis. J Pediatr Gastroenterol Nutr 2010; 50: 344-346.
47.
Rosenberg WM, Voelker M, Thiel R, et al. Serum Markers Detect the Presence of Liver Fibrosis: A Cohort Study Gastro. Gastroenterology 2014; 127: 1704-1713.
48.
Thrailkill KM, Bunn RC, Moreau CS, et al. Matrix metalloproteinase-2 dysregulation in type 1 diabetes. Diabetes Care 2007; 30: 2321-2326.
49.
Maxwell PR, Timms PM, Chandran S, Gordon D. Peripheral blood level alterations of TIMP-1, MMP-2 and MMP-9 in patients with type 1 diabetes. Diabet Med 2001; 18: 777-780.
50.
Peeters SA, Engelen L, Buijs J, et al. Plasma levels of matrix metalloproteinase-2, -3, -10, and tissue inhibitor of metalloproteinase-1 are associated with vascular complications in patients with type 1 diabetes: the EURODIAB prospective complications study. Cardiovasc Diabetol 2015; 14: 31.
51.
Wang Y, Yuan JM, Pan A, Koh WP .Tissue inhibitor matrix metalloproteinase 1 and risk of type 2 diabetes in a Chinese population. BMJ Open Diabetes Res Care 2020; 8: e001051.
52.
Bonnans C, Chou J, Werb Z. Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol 2014; 15: 786-801.
53.
Lee SW, Song KE, Shin DS, et al. Alterations in peripheral blood levels of TIMP-1, MMP-2, and MMP-9 in patients with type-2 diabetes. Diabetes Res Clin Pract 2005; 69: 175-179.
54.
Wadood SA, Shawk RA, Hashem R. Variants of MMP-9 and TIMP-1 levels could be a predictor of an early development of cardiovascular diseases in type 2 diabetes among Iraqi patients. Iraqi J Sci 2015; 56: 622-632.
55.
Alexander CM, Selvarajan S, Mudgett J, et al. Stromelysin-1 regulates adipogenesis during mammary gland involution. J Cell Biol 2001;152: 693-703.
56.
56 Buechler C, Krautbauer S, Eisinger K. Adipose tissue fibrosis. World J Diabetes 2015; 6 :548-553.
57.
Sun K, Tordjman J, Clément K, et al. Fibrosis and adipose tissue dysfunction. Cell Metab 2013;18: 470-477.
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
